140MO HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial

V. Guarneri, Aleix Prat, Oleguer Castillo et al.|Annals of Oncology|2022

Cited by 1